{
    "organizations": [],
    "uuid": "ef10cad142c8bd5c78e25c04d698ca065b383e3a",
    "author": "",
    "url": "https://www.reuters.com/article/brief-celyad-to-present-updates-on-cyad/brief-celyad-to-present-updates-on-cyad-01-at-american-association-for-cancer-research-annual-meeting-idUSFWN1RA120",
    "ord_in_thread": 0,
    "title": "BRIEF-Celyad To Present Updates On CYAD-01 At American Association For Cancer Research Annual Meeting",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 29, 2018 / 5:16 AM / in 13 minutes BRIEF-Celyad To Present Updates On CYAD-01 At American Association For Cancer Research Annual Meeting Reuters Staff 1 Min Read \nMarch 29 (Reuters) - CELYAD SA: \n* CELYAD TO PRESENT UPDATES ON CYAD-01 AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2018 \n* ‍PRECLINICAL STUDY SHOWS ADDING CD28 OR 4-1BB TO CYAD-01 BRINGS NO BENEFIT FOR IN VITRO ACTIVITY OF RECEPTOR​ \n* TO PRESENT UPDATE FROM THINK TRIAL, NEW SHRINK AND LINK TRIALS IN METASTATIC COLORECTAL CANCER​ \n* ‍THINK TRIAL: PRELIMINARY EVIDENCE OF NKG2D CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY (CYAD-01) CLINICAL ACTIVITY​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)",
    "published": "2018-03-29T08:14:00.000+03:00",
    "crawled": "2018-03-29T08:33:06.003+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "minute",
        "present",
        "update",
        "american",
        "association",
        "cancer",
        "research",
        "annual",
        "meeting",
        "reuters",
        "staff",
        "min",
        "read",
        "march",
        "reuters",
        "celyad",
        "sa",
        "celyad",
        "present",
        "update",
        "american",
        "association",
        "cancer",
        "research",
        "aacr",
        "annual",
        "meeting",
        "study",
        "show",
        "adding",
        "cd28",
        "brings",
        "benefit",
        "vitro",
        "activity",
        "present",
        "update",
        "think",
        "trial",
        "new",
        "shrink",
        "link",
        "trial",
        "metastatic",
        "colorectal",
        "trial",
        "preliminary",
        "evidence",
        "nkg2d",
        "chimeric",
        "antigen",
        "receptor",
        "cell",
        "therapy",
        "clinical",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}